3.17
price up icon4.97%   0.15
after-market Dopo l'orario di chiusura: 3.16 -0.010 -0.32%
loading
Precedente Chiudi:
$3.02
Aprire:
$3
Volume 24 ore:
3.49M
Relative Volume:
2.24
Capitalizzazione di mercato:
$299.40M
Reddito:
$829.00M
Utile/perdita netta:
$-399.90M
Rapporto P/E:
-0.7345
EPS:
-4.3159
Flusso di cassa netto:
$-23.20M
1 W Prestazione:
-40.41%
1M Prestazione:
-47.08%
6M Prestazione:
-40.19%
1 anno Prestazione:
-20.35%
Intervallo 1D:
Value
$3.00
$3.23
Intervallo di 1 settimana:
Value
$2.74
$5.43
Portata 52W:
Value
$2.74
$8.59

Myriad Genetics Inc Stock (MYGN) Company Profile

Name
Nome
Myriad Genetics Inc
Name
Telefono
801-584-3600
Name
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Name
Dipendente
2,700
Name
Cinguettio
@myriadgenetics
Name
Prossima data di guadagno
2026-07-30
Name
Ultimi documenti SEC
Name
MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, IDXX, NTRA, A

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
MYGN icon
MYGN
Myriad Genetics Inc
3.17 514.74M 829.00M -399.90M -23.20M -4.3159
TMO icon
TMO
Thermo Fisher Scientific Inc
564.75 207.93B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
194.78 138.14B 24.78B 3.68B 5.29B 5.1743
IDXX icon
IDXX
Idexx Laboratories Inc
588.09 43.87B 4.45B 1.10B 1.06B 13.59
NTRA icon
NTRA
Natera Inc
275.19 36.95B 2.50B -226.32M 71.51M -1.6412
A icon
A
Agilent Technologies Inc
139.20 38.94B 7.23B 1.41B 1.09B 4.979

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-21 Downgrade Scotiabank Sector Outperform → Sector Perform
2025-05-08 Downgrade Wolfe Research Outperform → Peer Perform
2025-05-07 Downgrade Wells Fargo Overweight → Equal Weight
2025-04-09 Downgrade Guggenheim Buy → Neutral
2025-03-12 Aggiornamento Piper Sandler Neutral → Overweight
2025-02-12 Iniziato Craig Hallum Buy
2024-12-10 Iniziato UBS Neutral
2024-12-09 Downgrade Leerink Partners Outperform → Market Perform
2024-09-19 Iniziato Morgan Stanley Equal-Weight
2024-08-28 Iniziato Wells Fargo Overweight
2024-06-27 Iniziato Scotiabank Sector Outperform
2024-06-03 Ripresa Jefferies Underperform
2024-05-08 Aggiornamento Leerink Partners Market Perform → Outperform
2023-12-21 Ripresa Piper Sandler Neutral
2023-12-19 Iniziato Wells Fargo Equal Weight
2023-12-14 Iniziato Guggenheim Buy
2023-12-13 Iniziato Wolfe Research Outperform
2023-07-05 Ripresa JP Morgan Underweight
2023-05-23 Aggiornamento Goldman Sell → Buy
2023-01-18 Aggiornamento Raymond James Mkt Perform → Outperform
2022-10-06 Iniziato Stephens Equal-Weight
2021-10-15 Ripresa Cowen Market Perform
2021-06-15 Iniziato Raymond James Mkt Perform
2021-06-03 Iniziato Goldman Sell
2019-09-26 Downgrade BofA/Merrill Neutral → Underperform
2019-08-14 Downgrade Piper Jaffray Overweight → Neutral
2019-08-02 Aggiornamento BofA/Merrill Underperform → Neutral
2019-08-01 Aggiornamento Barclays Underweight → Equal Weight
2019-07-29 Downgrade Needham Strong Buy → Hold
2019-07-09 Downgrade Cowen Outperform → Market Perform
2019-03-12 Reiterato Needham Strong Buy
2019-01-03 Iniziato Needham Strong Buy
2018-11-30 Aggiornamento Goldman Sell → Neutral
2018-10-10 Aggiornamento Piper Jaffray Neutral → Overweight
2018-07-11 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2018-03-21 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2018-01-29 Iniziato Goldman Sell
2018-01-22 Reiterato Barclays Equal Weight
2018-01-05 Iniziato BTIG Research Buy
2017-10-02 Ripresa Leerink Partners Mkt Perform
2017-08-09 Reiterato Barclays Equal Weight
2017-02-08 Aggiornamento Ladenburg Thalmann Sell → Neutral
2017-01-18 Iniziato Deutsche Bank Sell
2016-10-10 Downgrade Ladenburg Thalmann Neutral → Sell
Mostra tutto

Myriad Genetics Inc Borsa (MYGN) Ultime notizie

pulisher
Jul 27, 2026

Myriad Genetics rebuilt its AI platform after costs ballooned. Now, it can process documents in seconds. - Business Insider

Jul 27, 2026
pulisher
Jul 27, 2026

Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

TradingKey - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

MYGN|Myriad Genetics Inc|Price:5.610|Chg%:-0.090 - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 25, 2026
pulisher
Jul 24, 2026

Myriad Genetics, Inc. (MYGN) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jul 24, 2026
pulisher
Jul 24, 2026

Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance UK

Jul 24, 2026
pulisher
Jul 24, 2026

Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $6.14, Implies 8% Upside - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

Myriad Genetics Inc (MYGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 23, 2026

3 Reasons MYGN is Risky and 1 Stock to Buy Instead - Yahoo Finance

Jul 23, 2026
pulisher
Jul 23, 2026

Myriad Genetics stock trades sideways as investors digest recent revenue growth and precision oncolo - Ad-hoc-news.de

Jul 23, 2026
pulisher
Jul 23, 2026

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 - The Manila Times

Jul 23, 2026
pulisher
Jul 23, 2026

Myriad Genetics to Hold Second Quarter 2026 Earnings Conference Call on July 30 - Quiver Quantitative

Jul 23, 2026
pulisher
Jul 21, 2026

AWHL vs. MYGN: Which women's health diagnostics stock is better now? - MSN

Jul 21, 2026
pulisher
Jul 21, 2026

Myriad Genetics Launches New Four-in-One Prenatal Genetic Screen - Clinical Lab Products

Jul 21, 2026
pulisher
Jul 21, 2026

Myriad Genetics launches prenatal genetic screening test By Investing.com - Investing.com Nigeria

Jul 21, 2026
pulisher
Jul 21, 2026

Myriad Genetics launches prenatal genetic screening test - Investing.com

Jul 21, 2026
pulisher
Jul 21, 2026

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen - The Manila Times

Jul 21, 2026
pulisher
Jul 21, 2026

Myriad's one-draw test runs four prenatal screens at 8 weeks - Stock Titan

Jul 21, 2026
pulisher
Jul 20, 2026

Burning Rock and Myriad Announce Global Strategic Technology Licensing Partnership to Expand HRD Testing Worldwide - EIN News

Jul 20, 2026
pulisher
Jul 17, 2026

ETFs Investing in Myriad Genetics, Inc. Stocks - TradingView

Jul 17, 2026
pulisher
Jul 17, 2026

AWHL vs. MYGN: Which Women's Health Diagnostics Stock is Better Now? - The Globe and Mail

Jul 17, 2026
pulisher
Jul 17, 2026

MYGN Stock Price, Quote & Chart - ChartMill

Jul 17, 2026
pulisher
Jul 15, 2026

Myriad Genetics reports FirstGene prenatal screen achieves over 98 percent sensitivity and 99 percent specificity - Traders Union

Jul 15, 2026
pulisher
Jul 15, 2026

Is This the Right Time to Hold MYGN Stock in Your Portfolio? - Yahoo Finance

Jul 15, 2026
pulisher
Jul 15, 2026

Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - qz.com

Jul 15, 2026
pulisher
Jul 13, 2026

BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Announces Target Price $4 - Moomoo

Jul 13, 2026
pulisher
Jul 11, 2026

Myriad Genetics (MYGN) Q4 2024 earnings summary - Quartr

Jul 11, 2026
pulisher
Jul 10, 2026

Myriad Genetics (MYGN) Proxy filing Summary - Quartr

Jul 10, 2026
pulisher
Jul 10, 2026

AI upgrade boosts Prolaris Test predictive power at Myriad Genetics - Traders Union

Jul 10, 2026
pulisher
Jul 08, 2026

(MYGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Jul 08, 2026
pulisher
Jul 06, 2026

Myriad Genetics (MYGN) Surges 3.5%: Approaching Resistance at $6.51ADD Alert - dars.gov.et

Jul 06, 2026
pulisher
Jul 05, 2026

Myriad Genetics Q1 2026 Earnings: EPS Miss Clouds Diagnostic Growth OutlookGross Profit Margin - dars.gov.et

Jul 05, 2026
pulisher
Jul 02, 2026

Meta-analysis confirms Myriad's Prolaris test e... - Pluang

Jul 02, 2026
pulisher
Jul 02, 2026

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer - 富途牛牛

Jul 02, 2026
pulisher
Jul 02, 2026

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer - Yahoo Finance

Jul 02, 2026
pulisher
Jul 01, 2026

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS - BioSpace

Jul 01, 2026
pulisher
Jun 30, 2026

Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa

Jun 30, 2026
pulisher
Jun 30, 2026

MYGNMyriad Genetics Inc Latest SEC Filings - Finviz

Jun 30, 2026
pulisher
Jun 30, 2026

Sera Prognostics adds former Myriad Genetics CEO to board - Investing.com

Jun 30, 2026
pulisher
Jun 30, 2026

Sera Prognostics adds former Myriad CEO Mark Capone to board - Stock Titan

Jun 30, 2026
pulisher
Jun 30, 2026

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance

Jun 30, 2026
pulisher
Jun 29, 2026

Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Jun 29, 2026
pulisher
Jun 27, 2026

(MYGN) Risk Channels and Responsive Allocation - Stock Traders Daily

Jun 27, 2026
pulisher
Jun 27, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

Price to sales forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to book forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Myriad Genetics, Inc. Actuals & Estimates (NASDAQ:MYGN) - TradingView

Jun 27, 2026

Myriad Genetics Inc Azioni (MYGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
DGX DGX
$233.72
price up icon 0.76%
MTD MTD
$1,437.00
price down icon 0.55%
$203.01
price up icon 2.45%
IQV IQV
$228.20
price down icon 2.21%
WAT WAT
$396.08
price up icon 5.69%
A A
$139.20
price down icon 0.43%
Capitalizzazione:     |  Volume (24 ore):